Case report outlines significant improvement in facial muscle atrophy with upadacitinib, suggesting potential for broader use of janus kinase inhibitors.
Parry Romberg Syndrome (PRS) is a rare, slowly progressive degenerative disorder, marked by the progressive atrophy of facial muscles. Immunosuppressive medications for the treatment of PRS vary in efficacy, and surgical intervention is often utilized for optimal treatment outcomes. Here, we report a case of a 37-year-old female patient with PRS who demonstrated significant improvement after treatment with upadacitinib. The patient presented to the clinic with an indent on the forehead and pain around the area, consistent with Parry Romberg syndrome. Following the initiation of 15mg upadacitnib daily, and a subsequent increase in dosage to 30 mg upadacitinib daily, the indentation on her forehead resolved. This case highlights the utility of Janus kinase inhibitors as an effective treatment for PRS.
No takes yet. Share an insight, caveat, or question.
Aluya et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: